Developing and Implementing a Quality Measure for Glycemic Control
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Many patients with diabetes are under sub-optimal glycemic control. Central to the clinician's task in improving glycemic control is the management of hypoglycemic medication therapy, including the use of drugs such as insulin and sulfonylureas. Clinical trials have demonstrated that more intensive hypoglycemic medication therapy results in improved glycemic control. Yet quality measures for this critical process of care have not been developed and we know little about how physicians actually manage hypoglycemic medications.
| Condition |
|---|
|
Diabetes |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | Developing and Implementing a Quality Measure for Glycemic Control |
| Enrollment: | 0 |
| Study Completion Date: | December 2003 |
| Groups/Cohorts |
|---|
| Group 1 |
Detailed Description:
Background:
Many patients with diabetes are under sub-optimal glycemic control. Central to the clinician's task in improving glycemic control is the management of hypoglycemic medication therapy, including the use of drugs such as insulin and sulfonylureas. Clinical trials have demonstrated that more intensive hypoglycemic medication therapy results in improved glycemic control. Yet quality measures for this critical process of care have not been developed and we know little about how physicians actually manage hypoglycemic medications.
Objectives:
We propose to develop a quality measure that describes the intensity of physicians' hypoglycemic medication therapy. We will then provide feedback to VA physicians regarding their practices and access to experts in diabetes care to determine whether this intervention leads to improvements in glycemic control.
Methods:
The study was divided into two phases. During the first phase we used existing data to model the decision to increase hypoglycemic medications. At each medical visit, we determined whether an increase in medication therapy occurred. We then used recursive partitioning to develop a model that identified patient characteristics at the visit, such as recent laboratory results and diagnoses, associated with the decision to increase therapy. This model assigns a predicted probability of an increase in therapy to each visit. We used these predictions to define an intensity of hypoglycemic medication therapy for each physician that compared the actual to predicted number of increases over all patient-visits. The second phase was a randomized trial in which clinicians at experimental sites receive feedback on performance and access to expert opinion while usual care is provided at control sites. Feedback on performance was provided twice over 6 months. The change in intensity of treatment scores and glycosylated hemoglobin levels pre- and post-intervention at these sites were compared to performance of primary care physicians at control sites not receiving the intervention.
Status:
Completed.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Clinic patients with diabetes
Exclusion Criteria:
Contacts and Locations| United States, Massachusetts | |
| Bedford VA Medical Center | |
| Bedford, Massachusetts, United States, 01730 | |
| Principal Investigator: | Dan R. Berlowitz, MD MPH | Bedford VA Medical Center |
More Information
Publications:
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00012675 History of Changes |
| Other Study ID Numbers: | DII 99-205 |
| Study First Received: | March 14, 2001 |
| Last Updated: | May 23, 2012 |
| Health Authority: | United States: Federal Government |
ClinicalTrials.gov processed this record on May 22, 2013